Development and validation of a short-term breast health measure as a supplement to screening mammography
Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly...
Saved in:
Published in | Biomarker research Vol. 10; no. 1; pp. 1 - 9 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
25.10.2022
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 2050-7771 2050-7771 |
DOI | 10.1186/s40364-022-00420-1 |
Cover
Abstract | Background
There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities.
Methods
All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples.
Results
Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization.
Conclusions and relevance
The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. |
---|---|
AbstractList | There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities.BACKGROUNDThere is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities.All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples.METHODSAll protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples.Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization.RESULTSLogistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization.The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates.CONCLUSIONS AND RELEVANCEThe work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities. All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples. Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization. The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. Abstract Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities. Methods All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples. Results Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization. Conclusions and relevance The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities. Methods All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples. Results Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization. Conclusions and relevance The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities. Methods All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples. Results Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization. Conclusions and relevance The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of tear fluid processing, the ability to access key cancer biomarkers in high concentrations quickly and inexpensively is significantly enhanced. Tear fluid is a dynamic environment rich in both proteomic and genomic information, making it an ideal medium for exploring the potential for biological testing modalities. Methods All protocols involving human subjects were reviewed and approved by the University of Arkansas IRB committee (13-11-289) prior to sample collection. Study enrollment was open to women ages 18 and over from October 30, 2017-June 19, 2019 at The Breast Center, Fayetteville, AR and Bentonville, AR. Convenience sampling was used and samples were age/sex matched, with enrollment open to individuals at any point of the breast health continuum of care. Tear samples were collected using the Schirmer strip method from 847 women. Concentration of selected tear proteins were evaluated using standard sandwich ELISA techniques and the resulting data, combined with demographic and clinical covariates, was analyzed using logistic regression analysis to build a model for classification of samples. Results Logistic regression analysis produced three models, which were then evaluated on cases and controls at two diagnostic thresholds and resulted in sensitivity ranging from 52 to 90% and specificity from 31 to 79%. Sensitivity and specificity variation is dependent on the model being evaluated as well as the selected diagnostic threshold providing avenues for assay optimization. Conclusions and relevance The work presented here builds on previous studies focused on biomarker identification in tear samples. Here we show successful early classification of samples using two proteins and minimal clinical covariates. Keywords: Breast cancer, Cancer biomarkers, Biomarker validation, Tear fluids, ELISA, Receiver operator characteristic curves |
ArticleNumber | 76 |
Audience | Academic |
Author | Daily, Anna Klimberg, V. Suzanne Ravishankar, Prashanth Krone, Ryan Harms, Steve Wang, Wanyi |
Author_xml | – sequence: 1 givenname: Anna surname: Daily fullname: Daily, Anna email: anna@namidalab.com organization: Namida Lab Inc – sequence: 2 givenname: Prashanth surname: Ravishankar fullname: Ravishankar, Prashanth organization: Namida Lab Inc – sequence: 3 givenname: Wanyi surname: Wang fullname: Wang, Wanyi organization: Elite Research, LLC – sequence: 4 givenname: Ryan surname: Krone fullname: Krone, Ryan organization: Elite Research, LLC – sequence: 5 givenname: Steve surname: Harms fullname: Harms, Steve organization: The Breast Center-Medical Associates of Northwest Arkansas – sequence: 6 givenname: V. Suzanne surname: Klimberg fullname: Klimberg, V. Suzanne organization: Department of Surgery, University of Texas Medical Branch, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center |
BookMark | eNp9kktr3DAUhU1JoWmaP9CVoZt24VSvsa1NISR9DAQKfazFlXzt0WBLriSH5t9XM5OSTiiRQZKl7xxZ1-dlceK8w6J4TckFpW39PgrCa1ERxipCBCMVfVacMrIiVdM09OSf-YviPMYtya1tBaXytLDXeIujnyd0qQTXlbcw2g6S9a70fQll3PiQqoRhKnVAiKncIIxpU075ZQlYQtxRyzyPuDdJvowmIDrrhnKCafJDgHlz96p43sMY8fx-PCt-fvr44-pLdfP18_rq8qYyNW1TZXpmWiEN1lSuuGlR1JoQzJ2BXpimpZ3oUa4kAQROgTaaSt01BlsJGjU_K9YH387DVs3BThDulAer9gs-DApCsmZEJVEw3lLdS23EitZaS6OB9Bwbplm_8_pw8JoXPWFn8v0CjEemxzvObtTgb1X-PiEZyQZv7w2C_7VgTGqy0eA4gkO_RMUaJgmTvJEZffMI3foluFyqTPGmbkXNxQM1QL6Adb3P55qdqbpsWP6ngjOWqYv_UPnpcLImp6e3ef1I8O5IkJmEv9MAS4xq_f3bMdseWBN8jAF7ZWzaJyYfYkdFidrFUh1iqXIs1T6WimYpeyT9W8onRfwgihl2A4aHwjyh-gPFgfcf |
CitedBy_id | crossref_primary_10_1177_11772719231204508 |
Cites_doi | 10.1259/bjr.20211033 10.1002/ijc.28497 10.3322/caac.21583 10.1093/jnci/djaa080 10.3390/cancers12082037 10.1007/s10549-020-06000-x 10.1016/j.jprot.2016.05.006 10.1038/s41467-022-29151-5 10.1016/j.amjsurg.2022.03.029 10.1016/j.exer.2013.07.015 10.1001/jamanetworkopen.2020.7227 10.1148/radiol.2021203476 10.21873/anticanres.14290 10.1016/j.clbc.2017.08.012 10.1021/jacs.9b13874 10.1038/bjc.2015.346 10.3892/or.2012.1849 10.1080/14789450.2017.1285703 10.6004/jnccn.2010.0085 10.1021/pr800962q 10.1016/j.preteyeres.2012.06.002 10.1371/journal.pone.0267676 10.1007/s12195-017-0512-9 10.3389/fonc.2018.00496 10.1038/nrc3893 10.1148/radiol.2017161519 10.1148/radiol.2016161174 10.3322/caac.21708 10.1016/j.cdp.2007.04.006 10.7326/M21-3577 10.1007/s10549-013-2737-1 10.1016/j.bcp.2006.05.017 10.1016/S1470-2045(03)01037-4 10.3390/app12062884 10.7326/M15-2886 10.1007/s00330-022-08617-6 10.7150/ijbs.21635 10.1007/s13277-010-0137-2 10.1007/s00330-018-5668-8 10.1158/1055-9965.EPI-05-0824 10.1200/OP.20.00793 10.1016/S1470-2045(20)30398-3 10.1093/jnci/djh269 10.4049/jimmunol.1500365 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
Copyright_xml | – notice: The Author(s) 2022 – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
DBID | C6C AAYXX CITATION ISR 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s40364-022-00420-1 |
DatabaseName | Springer Nature OA Free Journals CrossRef Gale In Context: Science ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (ND) |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2050-7771 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_9e42381bf9bc4516bb9cba0f3e72b2fb PMC9594920 A724114322 10_1186_s40364_022_00420_1 |
GeographicLocations | United States--US |
GeographicLocations_xml | – name: United States--US |
GroupedDBID | 0R~ 53G 5VS 8FE 8FH AAFWJ AAJSJ AASML ACGFS ADBBV ADRAZ ADUKV AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC C6C CCPQU DIK EBLON EBS GROUPED_DOAJ HCIFZ HYE IAO IHR INH INR ISR ITC KQ8 LK8 M48 M7P M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC PUEGO RBZ ROL RPM RSV SOJ AAYXX CITATION PMFND ABUWG AZQEC DWQXO GNUQQ PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c618t-cf2c849ce61953c8e46b00e6b0caf4c781d4fe9590aea31a17b19bd7ce89abeb3 |
IEDL.DBID | M48 |
ISSN | 2050-7771 |
IngestDate | Wed Aug 27 01:31:19 EDT 2025 Thu Aug 21 18:39:08 EDT 2025 Thu Sep 04 21:22:12 EDT 2025 Fri Jul 25 10:20:04 EDT 2025 Tue Jun 17 21:31:28 EDT 2025 Tue Jun 10 20:21:51 EDT 2025 Fri Jun 27 04:38:37 EDT 2025 Tue Jul 01 00:23:01 EDT 2025 Thu Apr 24 23:11:02 EDT 2025 Sat Sep 06 07:27:45 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Cancer biomarkers Tear fluids Breast cancer Biomarker validation ELISA Receiver operator characteristic curves |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c618t-cf2c849ce61953c8e46b00e6b0caf4c781d4fe9590aea31a17b19bd7ce89abeb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s40364-022-00420-1 |
PQID | 2737684634 |
PQPubID | 2040162 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_9e42381bf9bc4516bb9cba0f3e72b2fb pubmedcentral_primary_oai_pubmedcentral_nih_gov_9594920 proquest_miscellaneous_2729029379 proquest_journals_2737684634 gale_infotracmisc_A724114322 gale_infotracacademiconefile_A724114322 gale_incontextgauss_ISR_A724114322 crossref_citationtrail_10_1186_s40364_022_00420_1 crossref_primary_10_1186_s40364_022_00420_1 springer_journals_10_1186_s40364_022_00420_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-10-25 |
PublicationDateYYYYMMDD | 2022-10-25 |
PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Biomarker research |
PublicationTitleAbbrev | Biomark Res |
PublicationYear | 2022 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | DS Buist (420_CR22) 2004; 96 S Inubushi (420_CR33) 2020; 40 C Yin (420_CR41) 2013; 142 Y-S Sun (420_CR6) 2017; 13 CD Lehman (420_CR13) 2017; 283 L Zhou (420_CR30) 2009; 8 A Vourtsis (420_CR9) 2019; 29 T Takeuchi (420_CR25) 2020; 142 MJ White (420_CR43) 2015; 195 AL Siu (420_CR12) 2016; 164 N Breen (420_CR8) 2007; 31 B Rogoz (420_CR4) 2018; 18 R Farber (420_CR10) 2021; 113 MD Ryser (420_CR2) 2022; 175 CE DeSantis (420_CR48) 2019; 69 E McKiernan (420_CR38) 2011; 32 SPSS I: IBM Corp (420_CR44) 2017 AR Bresnick (420_CR45) 2015; 15 C Gebhardt (420_CR47) 2006; 72 420_CR3 RW Pinsky (420_CR20) 2010; 8 EJ Cathcart-Rake (420_CR17) 2021; 17 420_CR5 BL Sprague (420_CR15) 2017; 283 M Azkargorta (420_CR26) 2017; 150 G Haars (420_CR21) 2005; 14 D Wang (420_CR40) 2018; 8 SW Duffy (420_CR19) 2020; 21 420_CR36 I Jatoi (420_CR7) 2003; 4 L Zhou (420_CR28) 2012; 31 S Funke (420_CR34) 2013; 117 420_CR32 VL Irvin (420_CR11) 2020; 3 RE Hendrick (420_CR18) 2021; 299 A Lebrecht (420_CR27) 2009; 6 J Li (420_CR46) 2022; 13 X Hu (420_CR49) 2021; 186 D Bohm (420_CR24) 2012; 28 NM Reynolds (420_CR42) 2018; 11 Breast Cancer Surveillance Consortium (420_CR14) 2017 420_CR23 A Daily (420_CR35) 2022; 17 L Wilkinson (420_CR1) 2022; 95 420_CR16 P Ravishankar (420_CR31) 2022; 12 L Zhou (420_CR29) 2017; 14 C Bergenfelz (420_CR37) 2015; 113 TZ Parris (420_CR39) 2014; 134 |
References_xml | – volume: 95 start-page: 20211033 issue: 1130 year: 2022 ident: 420_CR1 publication-title: Br J Radiol doi: 10.1259/bjr.20211033 – volume: 134 start-page: 1617 issue: 7 year: 2014 ident: 420_CR39 publication-title: Int J Cancer doi: 10.1002/ijc.28497 – volume: 69 start-page: 438 issue: 6 year: 2019 ident: 420_CR48 publication-title: CA Cancer J Clin doi: 10.3322/caac.21583 – volume: 113 start-page: 16 issue: 1 year: 2021 ident: 420_CR10 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djaa080 – ident: 420_CR36 doi: 10.3390/cancers12082037 – volume: 186 start-page: 209 issue: 1 year: 2021 ident: 420_CR49 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-020-06000-x – volume: 150 start-page: 359 year: 2017 ident: 420_CR26 publication-title: J Proteome doi: 10.1016/j.jprot.2016.05.006 – volume: 13 start-page: 1481 issue: 1 year: 2022 ident: 420_CR46 publication-title: Nat Commun doi: 10.1038/s41467-022-29151-5 – volume-title: Performance benchmarks for screening mammography; clinical demographics for 1,682,504 screening mammography examinations from 2007–2013. Updated year: 2017 ident: 420_CR14 – ident: 420_CR32 doi: 10.1016/j.amjsurg.2022.03.029 – volume: 117 start-page: 126 year: 2013 ident: 420_CR34 publication-title: Exp Eye Res doi: 10.1016/j.exer.2013.07.015 – volume: 3 start-page: e207227 issue: 6 year: 2020 ident: 420_CR11 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.7227 – volume: 299 start-page: 143 issue: 1 year: 2021 ident: 420_CR18 publication-title: Radiology doi: 10.1148/radiol.2021203476 – volume: 6 start-page: 75 issue: 2 year: 2009 ident: 420_CR27 publication-title: Cancer Genomics Proteomics – volume: 40 start-page: 3091 issue: 6 year: 2020 ident: 420_CR33 publication-title: Anticancer Res doi: 10.21873/anticanres.14290 – volume: 18 start-page: 246 issue: 3 year: 2018 ident: 420_CR4 publication-title: Clin Breast Cancer doi: 10.1016/j.clbc.2017.08.012 – volume: 142 start-page: 6617 issue: 14 year: 2020 ident: 420_CR25 publication-title: J Am Chem Soc doi: 10.1021/jacs.9b13874 – volume: 113 start-page: 1234 issue: 8 year: 2015 ident: 420_CR37 publication-title: Br J Cancer doi: 10.1038/bjc.2015.346 – volume: 28 start-page: 429 issue: 2 year: 2012 ident: 420_CR24 publication-title: Oncol Rep doi: 10.3892/or.2012.1849 – volume: 14 start-page: 189 issue: 3 year: 2017 ident: 420_CR29 publication-title: Expert review of proteomics doi: 10.1080/14789450.2017.1285703 – volume: 8 start-page: 1157 issue: 10 year: 2010 ident: 420_CR20 publication-title: J Natl Compr Cancer Netw doi: 10.6004/jnccn.2010.0085 – volume: 8 start-page: 1992 issue: 4 year: 2009 ident: 420_CR30 publication-title: J Proteome Res doi: 10.1021/pr800962q – volume: 31 start-page: 527 issue: 6 year: 2012 ident: 420_CR28 publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2012.06.002 – volume: 17 issue: 4 year: 2022 ident: 420_CR35 publication-title: PLoS One doi: 10.1371/journal.pone.0267676 – volume: 11 start-page: 37 issue: 1 year: 2018 ident: 420_CR42 publication-title: Cell Mol Bioeng doi: 10.1007/s12195-017-0512-9 – volume: 8 start-page: 496 year: 2018 ident: 420_CR40 publication-title: Front Oncol doi: 10.3389/fonc.2018.00496 – volume: 15 start-page: 96 issue: 2 year: 2015 ident: 420_CR45 publication-title: Nat Rev Cancer doi: 10.1038/nrc3893 – volume: 283 start-page: 59 issue: 1 year: 2017 ident: 420_CR15 publication-title: Radiology doi: 10.1148/radiol.2017161519 – volume: 283 start-page: 49 issue: 1 year: 2017 ident: 420_CR13 publication-title: Radiology doi: 10.1148/radiol.2016161174 – ident: 420_CR3 doi: 10.3322/caac.21708 – volume: 31 start-page: 220 issue: 3 year: 2007 ident: 420_CR8 publication-title: Cancer Detect Prev doi: 10.1016/j.cdp.2007.04.006 – volume: 175 start-page: 471 issue: 4 year: 2022 ident: 420_CR2 publication-title: Ann Intern Med doi: 10.7326/M21-3577 – volume: 142 start-page: 297 issue: 2 year: 2013 ident: 420_CR41 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2737-1 – volume-title: Released 2017, IBM SPSS statistics for windows, version 25.0 year: 2017 ident: 420_CR44 – volume: 72 start-page: 1622 issue: 11 year: 2006 ident: 420_CR47 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2006.05.017 – volume: 4 start-page: 251 issue: 4 year: 2003 ident: 420_CR7 publication-title: The lancet oncology doi: 10.1016/S1470-2045(03)01037-4 – volume: 12 start-page: 2884 issue: 6 year: 2022 ident: 420_CR31 publication-title: Appl Sci doi: 10.3390/app12062884 – volume: 164 start-page: 279 issue: 4 year: 2016 ident: 420_CR12 publication-title: Ann Intern Med doi: 10.7326/M15-2886 – ident: 420_CR5 doi: 10.1007/s00330-022-08617-6 – volume: 13 start-page: 1387 issue: 11 year: 2017 ident: 420_CR6 publication-title: Int J Biol Sci doi: 10.7150/ijbs.21635 – volume: 32 start-page: 441 issue: 3 year: 2011 ident: 420_CR38 publication-title: Tumour Biol doi: 10.1007/s13277-010-0137-2 – volume: 29 start-page: 1762 issue: 4 year: 2019 ident: 420_CR9 publication-title: Eur Radiol doi: 10.1007/s00330-018-5668-8 – volume: 14 start-page: 2634 issue: 11 year: 2005 ident: 420_CR21 publication-title: Cancer Epidemiology and Prevention Biomarkers doi: 10.1158/1055-9965.EPI-05-0824 – volume: 17 start-page: 305 issue: 6 year: 2021 ident: 420_CR17 publication-title: JCO Oncol Pract doi: 10.1200/OP.20.00793 – ident: 420_CR23 – ident: 420_CR16 – volume: 21 start-page: 1165 issue: 9 year: 2020 ident: 420_CR19 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30398-3 – volume: 96 start-page: 1432 issue: 19 year: 2004 ident: 420_CR22 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh269 – volume: 195 start-page: 1858 issue: 4 year: 2015 ident: 420_CR43 publication-title: J Immunol doi: 10.4049/jimmunol.1500365 |
SSID | ssj0000884119 |
Score | 2.2133377 |
Snippet | Background
There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the... There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the simplicity of... Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to the... Abstract Background There is a growing body of evidence to support tears as a non-traditional biological fluid in clinical laboratory testing. In addition to... |
SourceID | doaj pubmedcentral proquest gale crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 1 |
SubjectTerms | Biomarker validation Biomarkers Biomedical and Life Sciences Biomedicine Breast Breast cancer Cancer biomarkers Cancer Research ELISA Enzyme-linked immunosorbent assay Mammography Medical laboratories Mortality Proteins Proteomics Receiver operator characteristic curves Regression analysis Tear fluids Womens health |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (ND) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QJCQuiE9RGCggJA4QrUnz2uQ4ENNAggMwabfIyUvYk7YW0b7D_vvZTd_jlQm4cOmhcdrUdhy7cX5m7KWFYFJlvACQVujgQXgPVtRxQeDtqQ5LChQ_fa6PT_TH08XpTqkvygnL8MCZcQc2alpVfLI-UFFZ7y0-sExVbJRXyZP1LW25E0yNNtgYLaXdnJIx9UGvacdNUPI6KWop5GwlGgH7r5vl66mSv-2XjsvQ0R12e_If-WEe9112I7b32M1cUfLyPlvtJAFxaJccFWmVyybxLnHg_Rn624LsMfeUjz7wfBKSX-SfhRx6oqJan-OPQz50HC0LRrs4HH4BqLYZ4_oBOzl6_-3dsZiqKYhQSzOIkFQw2oZY085ZMFHXOOUiXgIkHRp0XHWKdmFLiFBJkI2X1i-bEI0FjzH3Q7bXdm18xLixyZTag5El9jEKIkaZsNRhWeHzgy6Y3HDWhQlqnCpenLsx5DC1y9JwKA03SsPJgr3e9vmRgTb-Sv2WBLalJJDs8QaqjptUx_1LdQr2gsTtCAajpTyb77Due_fh6xd32KBng66kUgV7NRGlDr8hwHRsATlByFkzyv0ZJc7TMG_eaJWb7ETv0HmkndC6Qp493zZTT8p9a2O3JhplS_TKGluwZqaNs8-ft7SrsxErHOWprSoL9majt79e_mf2Pv4f7H3CbimabrjQq8U-2xt-ruNT9OAG_2ycrFfg_kR9 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ba9YwNOiG4It4xeqUKIIPGtak-drkSTbZmIJDpoO9hSRNtg-2dq79Hvz3ntOm36zDvfShOekl55JzyzmEvNPWq1gox6zlmknvLHPOalaGBRZvj6Wv0VD8dlgeHMuvJ4uT5HDrUlrlJBMHQV23Hn3k27DNYsyoLOSny18Mu0ZhdDW10LhLNkEEK6Dzzd29w-9Hay8L8JDkXE-nZVS53UmMvDFMYkeCzRmf7UhD4f6b4vlmyuQ_cdNhO9p_SB4kPZLujIh_RO6E5jG5N3aW_P2ELP9KBqK2qSkQ1HJsn0TbSC3tzkDvZiiXqcO89J6OJyLpxeg0pLZDKOz5OTgQad9SkDBg9cLn0AsL6zHWun5Kjvf3fn4-YKmrAvMlVz3zUXgltQ8lRtC8CrIE1gtw8TZKX4ECK2PQC53bYAtueeW4dnXlg9LWge39jGw0bROeE6p0VLl0VvEc5ihhA1ibtpa-LuD5XmaETytrfCo5jp0vzs1geqjSjNgwgA0zYMPwjHxYz7kcC27cCr2LCFtDYrHs4UZ7dWoS7xkdJComLmrnsS-xcxpoMo9FqIQT0WXkLaLbYDmMBvNtTu2q68yXH0dmpwINB1RKITLyPgHFFv7B23R8AVYCK2jNILdmkMCvfj48UZVJ8qIz19SdkTfrYZyJOXBNaFcII3QO2lmlM1LNqHH2-_ORZnk21AwHfEot8ox8nOj2-uX_X94Xt3_rS3JfICPBVi4WW2Sjv1qFV6Cj9e51YsQ_PjA8Qw priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Nb9UwDI_QEBIXxKcoDBQQEgeIaNI0TY5jYhpIcAAm7RY5eQl7EmsR7Tvw32O3fY-VARKXHhqnH7Gd2LHzM2PPHESbKxsEgHRCxwAiBHDCpJrA27OJK3IU338wxyf63Wl9OsPk0FmYi_F7ac2rXlOgTFDOOclXKdDTuVrLyoyBWXO4209BbdFSuu25mD92Xaw9I0T_5Yn4cnLkbxHSceE5usluzBYjP5hYfItdSe1tdm2qIfnjDltfSPvh0K44is56KpTEu8yB92doYQuagXmgDPSBT2cf-fm0PcihJyqq7jluFfKh4ziXoH-Ln8PPAQV1QrW-y06O3nw-PBZz_QQRjbSDiFlFq11MhmJl0SZtUMkSXiJkHRs0VXVOrnYlJKgkyCZIF1ZNTNZBQC_7HttruzbdZ9y6bEsdwMoS-1gFCf1KWOm4qvD5URdMbkfWxxlcnGpcfPWjk2GNn7jhkRt-5IaXBXux6_Ntgtb4J_VrYtiOkmCxxxsoLX7WMu-SJhMkZBciVSAOwaH0lblKjQoqh4I9JXZ7Ar5oKbPmC2z63r_99NEfNGjLoPGoVMGez0S5w3-IMB9UwJEgrKwF5f6CEjUzLpu3UuXnmaH3aC5S7NNUOGZPds3Uk7Ld2tRtiEa5Eu2wxhWsWUjj4veXLe36bEQHR35qp8qCvdzK7a-X_314H_wf-UN2XZFi4SKu6n22N3zfpEdonQ3h8aiWPwGYyTOJ priority: 102 providerName: Springer Nature |
Title | Development and validation of a short-term breast health measure as a supplement to screening mammography |
URI | https://link.springer.com/article/10.1186/s40364-022-00420-1 https://www.proquest.com/docview/2737684634 https://www.proquest.com/docview/2729029379 https://pubmed.ncbi.nlm.nih.gov/PMC9594920 https://doaj.org/article/9e42381bf9bc4516bb9cba0f3e72b2fb |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfGJiReEJ8i26gMQuIBAknqOvYDQl21aVTahDYq7c2yHXurtCWsaSX233PnJIWwwRMvqRSf2_rud_adfb4j5I3UVvihMLHWqYyZNTo2RsuYuxEmb_fcFugoHh3zwxmbno3ONkhX7qhlYH2na4f1pGaLyw8_rm8-g8J_Cgov-Mea4WFajHHpiMEkBm9oC1Ymjs7YUWvuh5lZCJamsrs7c2fX3voU0vjfnqxvB1D-cYoaFqeDR-Rha1XScQODx2TDlU_I_abO5M1TMv8tNIjqsqAAr3lTTIlWnmpaXwADYpylqcEo9SVt7kfSq2YLkeoaqbACaNhOpMuKwnwDPjD8HXqlAcxN5utnZHaw_21yGLc1FmLLU7GMrc-sYNI6judpVjjGQREdPKz2zOZgzjLv5Egm2ulhqtPcpNIUuXVCagOe-HOyWVale0GokF4kzGiRJtBHZNqB76kLZoshfL9lEUk7zirbJiDHOhiXKjgigqtGGgqkoYI0VBqRd-s-35v0G_-k3kOBrSkxdXZ4US3OVauJSjqGZorx0lisUmyMBIQmfujyzGTeROQ1ilthcowSo2_O9aqu1ZfTEzXOAVVgYGZZRN62RL6CMVjdXmYATmA-rR7lbo8StNf2mztUqQ78CkxKPB_lQ-DZq3Uz9sSIuNJVK6TJZAK2Wi4jkvfQ2Bt-v6WcX4QM4iBPJrMkIu873P768b-zd_t_sHeHPMhQ3WD5z0a7ZHO5WLmXYNctzYBsjcfT0yl87u0ffz0ZkHsTPhmEXZJBUOSfmOpQgA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFS2QnBBPEWggEEgDhA18XoT-4BQC626tF2h0kq9Gdtx2pVoUppdof4U38hMHltCRW-95BCP8_A8PON5AbxWxsl8KG1oTKxC4awJrTUqTPyIirfnicvIUNydJFsH4svh6HAJfne5MBRW2cnEWlBnpaMz8lXcZslnlAzFx9OfIXWNIu9q10KjIYttf_4LTbbqw_gz4vcN55sb-5-2wrarQOiSWM5Cl3MnhXI-IQ-Sk14kSHoeL87kwqWowIncq5GKjDfD2MSpjZXNUuelMhZtT3zuDVgWlNE6gOX1jcnXvcWpDvKsiGPVZefIZLUS5OkLKWieGCQK494OWDcKuLwdXA7R_MdPW29_m3fhTqu3srWG0O7Bki_uw82mk-X5A5j-FXzETJExJOBp066JlTkzrDpGPT-kfYBZioOfsSYDk500h5TMVARFPUbrA0s2KxlKNLSy8XPYicH1b2prP4SDa1nvRzAoysI_BiZVLiNhjYwjnCO58Wjdmky4bIjPdyKAuFtZ7doS59Rp44euTR2Z6AYbGrGha2zoOIB3izmnTYGPK6HXCWELSCrOXd8oz450y-taeUGKkM2VddQH2VqFPBDlQ59yy3MbwCtCt6byGwXF9xyZeVXp8bc9vZaiRoUqLOcBvG2B8hL_wZk2XQJXgip29SBXepAoH1x_uKMq3cqnSl9wUwAvF8M0k2LuCl_OCYarCLXBVAWQ9qix9_v9kWJ6XNcoR3wKxaMA3nd0e_Hy_y_vk6u_9QXc2trf3dE748n2U7jNialQjeCjFRjMzub-GeqHM_u8ZUoG369bDvwBknp7QA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDI_QJhAvaHyJwoCAkHiAaE0vlyaPY3Da-JgQMGlvUZIm20msndbeA_89dtMeKwMkXu7h4ty1sZ3Ysf0zIS-09SrOlGPWcs2Ed5Y5ZzWTYY7g7VH6Ch3FT4dy_0i8P54fX6ri77Pdx5BkqmlAlKa62zmvYlJxJXdageEzhpnoKHU5A_9nU-DRh-Faube-ZQEdEpzrsVrmj1MnJ1IP3H91e76aMvlb3LQ_jhZb5NZgR9LdxPjb5Fqo75DrqbPkj7tkeSkZiNq6oiBQy9Q-iTaRWtqegt3NcF-mDvPSO5oqIulZujSktkUq7PnZXyDSrqGww4DXC49DzyyIb8K6vkeOFu--7e2zoasC85KrjvlYeCW0DxIjaF4FIUH1Anx4G4UvwYAVMei5zm2wM2556bh2VemD0taB732fbNRNHR4QqnRUuXBW8RzmqMIG8DZtJXw1g9_3IiN8XFnjB8hx7Hzx3fSuh5ImccMAN0zPDcMz8mo95zwBbvyT-g0ybE2JYNn9F83FiRl0z-gg0DBxUTuPfYmd0yCTeZyFsnBFdBl5juw2CIdRY77NiV21rTn4-sXslmDhgElZFBl5ORDFBt7B26F8AVYCEbQmlNsTStBXPx0epcoM-0VrwIjEiKicwZo9Ww_jTMyBq0OzQppC52CdlToj5UQaJ68_HamXpz1mOPBT6CLPyOtRbn_9-d-X9-H_kT8lNz6_XZiPB4cfHpGbBeoYnPLFfJtsdBer8BjMt8496TX0J8DpPr0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+and+validation+of+a+short-term+breast+health+measure+as+a+supplement+to+screening+mammography&rft.jtitle=Biomarker+research&rft.au=Anna+Daily&rft.au=Prashanth+Ravishankar&rft.au=Wanyi+Wang&rft.au=Ryan+Krone&rft.date=2022-10-25&rft.pub=BMC&rft.eissn=2050-7771&rft.volume=10&rft.issue=1&rft.spage=1&rft.epage=9&rft_id=info:doi/10.1186%2Fs40364-022-00420-1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_9e42381bf9bc4516bb9cba0f3e72b2fb |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2050-7771&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2050-7771&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2050-7771&client=summon |